ViCentra Announces Appointment of Tom Arnold as CEO
ViCentra B.V., the company renowned for the Kaleido insulin patch pump, is excited to announce the appointment of Tom Arnold as its new Chief Executive Officer. Tom's extensive background in the MedTech industry positions him perfectly to lead the company in its forthcoming endeavors, particularly as ViCentra focuses on scaling manufacturing, expanding in Europe, and preparing to enter the U.S. market with the groundbreaking Kaleido insulin delivery system.
A Leader in MedTech with a Passion for Diabetes Care
Tom Arnold is not just any leader; he brings with him nearly 25 years of leadership expertise in diabetes and medical technology. His career includes significant contributions to leading companies such as Medtronic, PROCEPT BioRobotics, Boston Scientific, and Sorin Group. His pivotal role at Medtronic involved launching the first hybrid closed-loop insulin pump system, supported by innovative commercialization strategies and improved patient access to diabetes management solutions.
A Vision for Growth and Accessibility
Jan Keltjens, the Chairman of the Board at ViCentra, expressed enthusiasm about Tom's appointment. "With his extensive understanding of commercial strategy and profound knowledge of the healthcare sector, Tom is uniquely qualified to lead ViCentra into its next growth phase. We are eager to witness how he will elevate the Kaleido brand and enhance the lives of individuals living with diabetes," he remarked.
A Personal Connection to Diabetes
For Tom, the drive to innovate in diabetes care is rooted in personal experience. His youngest daughter was diagnosed with type 1 diabetes at just 11 months old. Having supported her through the journey alongside using an insulin pump for 17 years, Tom has an intimate understanding of the unique challenges faced by diabetes patients. This connection enhances his commitment to developing impactful technologies.
Empowering Users with Innovative Technology
In his own words, Tom stated, "Understanding the unique challenges of diabetes management as both a physician and a father amplifies my dedication to the development of user-friendly technologies. Kaleido's goal to provide discreet and empowering insulin therapy not only resonates with my professional ethos but also with my personal experiences." His leadership comes at a pivotal moment for ViCentra, amid efforts to deliver innovations that substantially improve diabetes management.
About the Kaleido Insulin Patch Pump
The Kaleido system is a revolutionary product that offers numerous advantages in insulin delivery. It stands out as one of the smallest and most lightweight patch pumps available, designed specifically for those living with diabetes. The advanced DBLG1 AID software works harmoniously with the patch pump, creating a state-of-the-art artificial pancreas system that allows users personalized freedom in their insulin therapy.
Current Users and Future Aspirations
Currently, Kaleido boasts approximately 2,500 active users across several European nations, including strong markets in the Netherlands, France, and Germany. User feedback has been overwhelmingly positive, confirming the product's rapid adoption and effectiveness. ViCentra is strategically focused on enhancing its international commercialization efforts and leveraging its promising portfolio strategy to continue meeting user needs effectively.
About ViCentra
Founded in 2013, ViCentra B.V. operates out of Utrecht and specializes in developing, manufacturing, and marketing diabetes management solutions. The company’s flagship product, the Kaleido patch pump, is CE-marked under MDR and is available in multiple European markets. Its design caters to various lifestyles, offering features like automated insulin delivery and a choice between wearing it as a patch or with a pocket tube. With its availability in 10 distinct color combinations, Kaleido provides both functionality and aesthetics.
Frequently Asked Questions
Who is the new CEO of ViCentra?
Tom Arnold has recently been appointed as the Chief Executive Officer of ViCentra.
What is the Kaleido insulin patch pump?
Kaleido is an innovative insulin delivery system recognized for its small size, lightweight design, and advanced capabilities in diabetes management.
What is Tom Arnold's experience in the MedTech industry?
With nearly 25 years of experience, Tom has held leadership roles in renowned companies, significantly impacting diabetes management technologies.
How many active users does Kaleido currently have?
Kaleido has approximately 2,500 active users in Europe, with considerable growth observed in user adoption.
What sets ViCentra apart in the medical technology field?
ViCentra focuses on developing user-friendly, cutting-edge technology that empowers individuals with diabetes by offering innovative insulin delivery solutions.
